LABORATOIRES THEA

Ocular Hypertension: Over 60 Companies Advance Clinical Trial Pipeline

4 months ago

• The ocular hypertension market is expanding due to increased prevalence of conditions affecting aqueous humor outflow, leading to elevated intraocular pressure (IOP). • Advancements like sustained-release implants and micro-dosing technologies are enhancing patient compliance and improving outcomes in ocular hypertension treatment. • Enhanced imaging techniques, such as optical coherence tomography (OCT), facilitate early diagnosis and intervention, contributing to the growth of the ocular hypertension market. • Over 60 companies are actively developing more than 70 pipeline drugs for ocular hypertension, signaling robust innovation and future growth potential in the domain.

Emerging Therapies Offer Hope for Usher Syndrome Patients

a year ago

• The Usher Syndrome market is poised for growth with emerging therapies addressing the root cause of the disease, offering alternatives to supportive care. • Ultevursen, an investigational RNA therapy, targets the USH2A gene mutation and is currently in Phase II/III trials, showing promise in restoring functional usherin protein. • Nacuity Pharmaceuticals' NPI-001, a free radical scavenger, is in Phase I/II trials, aiming to reduce oxidative stress and preserve photoreceptor cells in Usher Syndrome patients. • The US has the highest prevalent cases of Usher Syndrome, with approximately 21,000 cases in 2023, highlighting the significant unmet need for effective treatments.